Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.

Abstract

In 7 of 8 children with idiopathic pulmonary arterial hypertension treated with intravenous epoprostenol for >1 year, concomitant use of bosentan allowed a reduction of epoprostenol and decreased its associated side effects without deterioration of clinical and hemodynamic parameters. In 3 children with normal or near-normal pulmonary artery pressure on epoprostenol, the addition of bosentan allowed discontinuation of epoprostenol and stabilization of hemodynamics for up to 1 year.

• Authors: D Dunbar Ivy, Aimee Doran, Lori Claussen, Deborah Bingaman, Anji Yetman
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 93 Issue 7 Pg. 943-6 (Apr 01 2004) ISSN: 0002-9149 [Print] United States
• PMID: 15050507 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antihypertensive Agents
• Sulfonamides
• Epoprostenol
• Bosentan

Topics

• Adolescent
• Antihypertensive Agents (administration & dosage, adverse effects)
• Blood Pressure (physiology)
• Bosentan
• Child
• Child, Preschool
• Dose-Response Relationship, Drug
• Drug Therapy, Combination
• Epoprostenol (administration & dosage, adverse effects)
• Female
• Humans
• Hypertension, Pulmonary (drug therapy, physiopathology)
• Male
• Sulfonamides (administration & dosage)
• Vascular Resistance (physiology)